International scientists team found that patients with chronic lymphocytes or small lymphocytic lymphoma to reduce statin – to reduce cholesterol during the beginning of anti -cancerrol treatment had a risk of 61% less cancer than those who do not receive statin. Published in İş Magazine Blood progress.
“This is the first systematic work of the connection between the use of statin and survival in patients with modern -targeted drugs such as Ibrutinib, Ahmad Abuelva, Associate Professor of Shargie University. “Our results show that there is a strong connection between the use of statin and the healing of survival in this patient group.”
The study analyzed the data of 1467 patients who participated in four international clinical studies from 2012 to 2019. Approximately one -third (29%) took statin at the beginning of the treatment. He was treated with İBRUTİNİB in combination with both monoraray and other drugs. Most (92%) were diagnosed with chronic lympolecosis.
After five years of observation, researchers have found that the use of statin was associated with a decrease in a 61% decrease in the risk of death from cancer, a decrease in the risk of death for any reason, and a decrease in the likelihood of progression of the disease. At the same time, the use of statin has not increased the risk of serious side effects.
Previously KnownWhat makes healing after surgery to change the hip joint.
What are you thinking?
Source: Gazeta
Barbara Dickson is a seasoned writer for “Social Bites”. She keeps readers informed on the latest news and trends, providing in-depth coverage and analysis on a variety of topics.